Silgan (SLGN) Q2 2025 earnings summary

Executive summary

• Achieved record Q2 Adjusted EBIT of $193 million, 15% Adjusted EPS growth, and 11% net sales increase to $1.54 billion, driven by dispensing and pet food markets, Weener acquisition integration, and cost reduction initiatives.

• First half Adjusted EPS up 17% year-over-year, with record first half Adjusted EBIT and EBITDA.

• Dispensing and Specialty Closures segment delivered over 40% growth in dispensing products and record Adjusted EBIT, supported by Weener acquisition.

• Metal Containers segment saw mid-single digit growth in pet food, stable total volumes, and 21% higher Adjusted EBIT year-over-year.

• Custom Containers segment improved EBIT margins by 190 basis points, with comparable volumes up 2% after cost reduction exits.

Financial highlights

• Q2 2025 net sales reached $1.54 billion, up 11.4% year-over-year, driven by dispensing products and Weener acquisition.

• Record Q2 Adjusted EBIT of $193 million, up 17% year-over-year, with all segments contributing.

• Adjusted EPS of $1.01, up $0.13 or 15% from prior year.

• Gross profit for Q2 2025: $299.1 million, gross margin 19.4% (up 0.9 pts year-over-year).

• Dispensing and Specialty Closures sales up 24% year-over-year; Metal Containers sales up 4%; Custom Containers sales down 3%.

Outlook and guidance

• 2025 Adjusted EPS guidance revised to $3.85–$4.05 (9% increase at midpoint vs. 2024), reflecting $10 million EBIT headwinds each from North American beverage specialty closures and a customer bankruptcy in Metal Containers.

• 2025 Adjusted EBITDA expected to exceed $1 billion for the first time.

• Free Cash Flow estimate for 2025 revised to $430 million, a 10% increase from prior year, with CapEx of $300 million.

• Q3 2025 Adjusted EPS expected at $1.18–$1.28; net sales to grow mid to high 20% rate; volumes to increase mid-single digit percentage.

• Management expects sufficient liquidity and ongoing compliance with all financial covenants in 2025.